No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
JNJ240712P144000
- 0.03
- +0.01+50.00%
15min DelayClose Jul 11 16:00 ET
0.05High0.02Low
0.05Open0.02Pre Close126 Volume476 Open Interest144.00Strike Price367.00Turnover43.96%IV3.83%PremiumJul 12, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type-0.0192Delta0.0166Gamma7485.00Leverage Ratio-0.0899Theta0.0000Rho-143.96Eff Leverage0.0030Vega
Intraday
- 5D
- Daily
News
Stifel Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $155
Stifel analyst Rick Wise maintains $Johnson & Johnson(JNJ.US)$ with a hold rating, and maintains the target price at $155.According to TipRanks data, the analyst has a success rate of 57.5% and a
Earnings Preview: JNJ to Report Financial Results Pre-market on July 17
$Johnson & Johnson(JNJ.US)$ is scheduled to release its financial results pre-market on July 17. Earnings PreviewAnalysts estimate $Johnson & Johnson(JNJ.US)$ to post revenue of USD22.31 billion for 2
Stifel Nicolaus Remains a Hold on Johnson & Johnson (JNJ)
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $167
Morgan Stanley analyst Terence Flynn maintains $Johnson & Johnson(JNJ.US)$ with a hold rating, and maintains the target price at $167.According to TipRanks data, the analyst has a success rate of 64.8
Johnson & Johnson (JNJ.US) announced the acquisition of Yellow Jersey will bring a cost impact of 1.25 billion US dollars, it is expected to dilute this year's adjusted EPS by 0.56 US dollars.
Johnson & Johnson announced on Thursday that the acquisition of Yellow Jersey Therapeutics will result in an expense impact of approximately $1.25 billion.
J&J to Recognize $1.25B Impact From Yellow Jersey Acquisition
Comments
Big potiental for Russell 2000, REITs & Bond markets in second half year of 2024.
AI stocks may be struggling in short term but fundamentals are still very strong. A little pullback is normal.
AI stocks may be struggling in short term but fundamentals are still very strong. A little pullback is normal.
loading...
12
1
For the last 128 years, the iconic Dow Jones Industrial Average $Dow Jones Industrial Average(.DJI.US$ has served as the premier health barometer for Wall Street. What began as a 12-stock index that primarily contained industrial companies has transformed into a 30-component index comprised of time-tested, multinational businesses that have consistently delivered for investors over the long run.
While most Dow Jones stocks aren't...
While most Dow Jones stocks aren't...
+1
4
It was great to be on Ausbiz, 'the call, with Ted Alexander from BML Funds and Nadine Blayney today.
I was asked about my thinking on the mentioned 11 US stocks. I presented a brief summary of my deep research dive, looking at company fundamentals and technical indicators, while considering macroeconomic policy, trends, government stimulus, clean...
I was asked about my thinking on the mentioned 11 US stocks. I presented a brief summary of my deep research dive, looking at company fundamentals and technical indicators, while considering macroeconomic policy, trends, government stimulus, clean...
14
The whales ....
$Microsoft(MSFT.US$ $Amazon(AMZN.US$ $Alphabet-C(GOOG.US$ $Apple(AAPL.US$ $Meta Platforms(META.US$ $NVIDIA(NVDA.US$ $Visa(V.US$ $JPMorgan(JPM.US$ $Berkshire Hathaway-B(BRK.B.US$ $MasterCard(MA.US$ $UnitedHealth(UNH.US$ $Johnson & Johnson(JNJ.US$ $Exxon Mobil(XOM.US$ $Eli Lilly and Co(LLY.US$
$Microsoft(MSFT.US$ $Amazon(AMZN.US$ $Alphabet-C(GOOG.US$ $Apple(AAPL.US$ $Meta Platforms(META.US$ $NVIDIA(NVDA.US$ $Visa(V.US$ $JPMorgan(JPM.US$ $Berkshire Hathaway-B(BRK.B.US$ $MasterCard(MA.US$ $UnitedHealth(UNH.US$ $Johnson & Johnson(JNJ.US$ $Exxon Mobil(XOM.US$ $Eli Lilly and Co(LLY.US$
11
Read more